# Verici Dx revenue growth signals commercial inflection point

- Link: https://www.directorstalkinterviews.com/verici-dx-revenue-growth-signals-commercial-inflection-point/4121239566
- Published: 2026-02-16T12:15:00+00:00
- Author: Amilia Stone

[Verici Dx](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)
has delivered a clear step forward in commercial execution, reporting revenue of
approximately $3.8 million for the year ended 31 March 2025, driven primarily by
accelerating adoption of its Tutivia post-transplant test and expanding US insurance
coverage.

The increase in revenue reflects higher test volumes as transplant centres integrate
Tutivia more consistently into patient monitoring protocols. The company’s strategy
has centred on demonstrating clinical utility and then converting that validation
into routine usage.

A central driver has been broader reimbursement support. During the period, Tutivia
was added as an in-network test under an agreement with Blue Cross Blue Shield, 
materially improving patient access. In-network status reduces out-of-pocket uncertainty
and administrative barriers, both of which can slow adoption in diagnostics markets.

Management has indicated that US coverage continues to widen beyond this agreement,
further reinforcing the reimbursement foundation. As payer relationships deepen,
the commercial model becomes less speculative and more execution-driven.

_**[Verici Dx Plc](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)**(
LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests
forming a kidney transplant diagnostics platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient outcomes._

Share on: